Endologix, Inc. reaffirmed earnings guidance for the third quarter ending September 30, 2019 and full year 2019. The Company anticipates revenue for the third quarter ending September 30, 2019 in the range of $35 million to $37 million. The Company reaffirms its previously issued annual guidance and continues to expect 2019 revenue of at least $140 million.